Massachusetts Institute of Technology

Boston University

Unversität Zürich

Shelby Doyle

Angela N Koehler

Becky Leifer

Arturo Jose Vegas

David C Freeman

Nicholas B Struntz

Marco Wachtel

Daniel Sheehy

Andre Richters

Kelly Tan

Stephen Thomas Nestor

Luke Ceo

Madeleine Henley

Beat W Schaefer

Sean Quinnell

The technology described herein is directed to IL-4 and/or IL-13 inhibitors and uses thereof.

Small molecule inhibitors of Interleukin-4

The present disclosure provides compounds having the general formula P-L-U, or pharmaceutically acceptable salts thereof, wherein P is a FOXO1 fusion protein binding moiety, L is a bivalent linker, and U is an ubiquitin ligase binding moiety. Also provided are pharmaceutical compositions containing such compounds and methods of using such compounds.

Small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1

Provided herein are compounds useful for modulating the activity of an androgen receptor, or a variant thereof, and related compositions and methods. Compounds of the invention are useful for antagonizing the androgen receptor splice variant AR-v7, and for the treatment of castration-resistant prostate cancer.

Small molecule modulators of the androgen receptor

Growing community of inventors

Cambridge, MA, United States of America

Shelby Doyle